Publications by authors named "Neil A O'Brien"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

500

Total Likes

15

Extended Reach

877

Social Features

3
P
Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
Martina S J McDermott, Neil A O'Brien, Benjamin Hoffstrom, KeWei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny J Hong

Clin Cancer Res· June 2023

Videos about Article: user user

2 1

View All Article and Social Media Activity
D
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Neil A O'Brien, Martina S J McDermott, Jun Zhang, Ke Wei Gong, Ming Lu

Mol Cancer Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina S J McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Rohan Diwanji, Neil A O'Brien, Jiyoung E Choi, Beverly Nguyen, Tyler Laszewski

Cancer Immunol Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
Neil A O'Brien, Holly K T Huang, Martina S J McDermott, Athena M Madrid, Tong Luo

Mol Cancer Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Christen Dillard, Meagan Kiyohara, Vei Mah, Sean P McDermott, Dana Bazzoun, Neil A O'Brien

Mol Cancer Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
Neil A O'Brien, Martina S J McDermott, Dylan Conklin, Tong Luo, Raul Ayala

Breast Cancer Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Alexandra Canonici, Laura Ivers, Neil T Conlon, Kasper Pedersen, Nicola Gaynor, Neil A O'Brien

Invest New Drugs· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells.
Martina S J McDermott, Neil Conlon, Brigid C Browne, Adam Szabo, Naoise C Synnott, Neil A O'Brien

Cancers (Basel)· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O'Leary, Neil A O'Brien

BMC Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Alexandra Canonici, Zulfiqar Qadir, Neil T Conlon, Denis M Collins, Neil A O'Brien

Invest New Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
Martina S J McDermott, Alexandra Canonici, Laura Ivers, Brigid C Browne, Stephen F Madden, Neil A O'Brien

Int J Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Sara A Hurvitz, Ondrej Kalous, Dylan Conklin, Amrita J Desai, Judy Dering, Neil A O'Brien

Breast Cancer Res Treat· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
Neil A O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
Martina Sj McDermott, Brigid C Browne, Neil T Conlon, Neil A O'Brien, Dennis J Slamon

Mol Cancer· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.
Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Neil A O'Brien

Oncotarget· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Gottfried E Konecny, Teodora Kolarova, Neil A O'Brien, Boris Winterhoff, Guorong Yang

Mol Cancer Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Zev A Wainberg, Adrian Anghel, Amy M Rogers, Amrita J Desai, Ondrej Kalous, Neil A O'Brien

Mol Cancer Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Brigid C Browne, Alex J Eustace, Susan Kennedy, Neil A O'Brien, Kasper Pedersen

Breast Cancer Res Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Ondrej Kalous, Dylan Conklin, Amrita J Desai, Neil A O'Brien, Charles Ginther

Mol Cancer Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
Neil A O'Brien, Brigid C Browne, Lucy Chow, Yuhua Wang, Charles Ginther

Mol Cancer Ther· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mammaglobin a in breast cancer: existence of multiple molecular forms.
Neil A O'Brien, Norma O'Donovan, Bríd Ryan, Arnold D K Hill, Enda McDermott

Int J Cancer· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis